April 7 (Reuters) - Insmed (INSM.O), opens new tab said on Tuesday it ‌would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage ...

Confused between Python and R? Discover which language dominates data science in 2026. Compare AI power, visualization, and real-world use cases to pick the right career path. Whether beginner or pro, ...

A new study from Monash University reveals that adults with Attention-Deficit/Hyperactivity Disorder (ADHD) experience brief sleep-like brain activity during the day ...

On March 9, New York State Governor Kathy Hochul announced a pilot program, including six New York counties, to provide free private well PFAS tests to eligible residents. Locals who get their ...

Sanofi has backed the $75 million series B of a rhinovirus-focused biotech with a former FDA acting commissioner at the helm. Altesa BioSciences unveiled back in 2022 with $4 million in seed funding ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

As Priovant works toward approval of potential blockbuster brepocitinib as a treatment for dermatomyositis, the North Carolina biotech has presented promising results for the TYK2/JAK1 inhibitor in ...

Pfizer (PFE) announced on Tuesday that a mid-stage trial evaluating a monthly maintenance dosing regimen of its experimental obesity drug indicated that the GLP-1 receptor agonist PF’3944 (MET-097i) ...

DALLAS—As pay TV operators continue to struggle with cord cutting and streaming platforms seeks to retain fickle consumers who regularly cancel subscriptions, a new study from Parks Associates takes a ...

We might earn a commission if you make a purchase through one of the links. The McClatchy Commerce Content team, which is independent from our newsroom, oversees this content. Passing the Series 24 ...